Results from the Phase III STREAM stage 2 trial demonstrate the efficacy and safety of an all-oral regimen containing bedaquiline for multidrug-resistant pulmonary tuberculosis.
FDA gives full approval to Johnson & Johnson’s Sirturo for the treatment of pulmonary tuberculosis caused by rifampicin- and isoniazid-resistant TB
Leave a comment
